ClinConnect ClinConnect Logo
Search / Trial NCT03995342

The Correlation and Intervention of Intestinal Flora and Frailty in the Elderly

Launched by XIJING HOSPITAL · Jun 21, 2019

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Frailty, Flora

ClinConnect Summary

100 healthy controls, 100 pre-frailty and 100 frailty elderly will be included. the healthy controls will be received no intervention. The pre-frailty will be randomized at a 1:1 ratio to receive prebiotics (inulin) or placebo (maltodextrin) . The degree of improvements and correlation in frailty will be evaluated three months later.Similarly,the frailty also will be randomized at a 1:1 ratio to receive prebiotics (inulin) or placebo (maltodextrin). The degree of improvements and correlation in frailty will be evaluated three months later.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥65 years;
  • Can get up from a chair and walk 6 meters
  • Clearly consciousness, able to read or use words to express and communicate without difficulty
  • Agree and accept the study plan
  • Exclusion Criteria:
  • Acute and chronic inflammatory disease of the intestine within 3 months
  • Use of antibiotics, probiotics, prebiotics or synthetics, laxatives or diarrhea medications, proton pump inhibitors or gastric motility drugs within 1 month
  • Dementia
  • mental illness or blindness
  • acute infection
  • cancer

About Xijing Hospital

Xijing Hospital, a prominent medical institution affiliated with the Fourth Military Medical University in Xi'an, China, is dedicated to advancing healthcare through innovative clinical research. Renowned for its comprehensive range of medical services and expertise in various specialties, Xijing Hospital actively sponsors clinical trials aimed at evaluating new therapies, improving patient outcomes, and contributing to scientific knowledge. With a commitment to ethical standards and patient safety, the hospital fosters collaboration among multidisciplinary teams to drive forward the development of effective treatment options that address critical health challenges.

Locations

Xi'an, Shaanxi, China

Patients applied

0 patients applied

Trial Officials

Wang xiao ming

Study Chair

Director of geriatrics

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials